Joint Global Coordinator
Kempen & Co acted as Joint Global Coordinator in BioInvent’s SEK 962m Capital Increase
BioInvent is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumours, respectively. The Company has two other programmes progressing in the clinic and a portfolio of additional pre-clinical drug candidates. The Company’s validated, proprietary F.I.R.S.T.™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: